These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 25043539)

  • 1. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy studies].
    Pedro-Botet J; Flores-Le Roux JA
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():17-9. PubMed ID: 25043542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
    Díaz Rodríguez Á
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts.
    Grupo de trabajo de Dislipemia Aterogénica de la Sociedad Española de Arteriosclerosis y Grupo Europeo de Expertos
    Clin Investig Arterioscler; 2017; 29(4):168-177. PubMed ID: 28433209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
    Chapman MJ; Redfern JS; McGovern ME; Giral P
    Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
    Moutzouri E; Kei A; Elisaf MS; Milionis HJ
    Vasc Health Risk Manag; 2010 Aug; 6():525-39. PubMed ID: 20730069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
    González Santos P
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.
    Hernández-Mijares A; Ascaso JF; Blasco M; Brea Á; Díaz Á; Mantilla T; Pedro-Botet J; Pintó X; Millán J;
    Clin Investig Arterioscler; 2019; 31(2):75-88. PubMed ID: 30262442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.